Compare Piramal Healthcare with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUVEN LIFESCIENCES - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUVEN LIFESCIENCES PIRAMAL ENTERPRISES/
SUVEN LIFESCIENCES
 
P/E (TTM) x 18.2 19.8 92.1% View Chart
P/BV x 1.2 4.0 28.9% View Chart
Dividend Yield % 1.5 0.5 291.2%  

Financials

 PIRAMAL ENTERPRISES   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
SUVEN LIFESCIENCES
Mar-19
PIRAMAL ENTERPRISES/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs3,303338 978.0%   
Low Rs1,797169 1,060.7%   
Sales per share (Unadj.) Rs716.552.1 1,374.4%  
Earnings per share (Unadj.) Rs79.76.8 1,166.8%  
Cash flow per share (Unadj.) Rs107.98.6 1,259.1%  
Dividends per share (Unadj.) Rs28.001.50 1,866.7%  
Dividend yield (eoy) %1.10.6 185.6%  
Book value per share (Unadj.) Rs1,477.565.3 2,263.1%  
Shares outstanding (eoy) m184.45127.28 144.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.9 73.2%   
Avg P/E ratio x32.037.1 86.2%  
P/CF ratio (eoy) x23.629.6 79.9%  
Price / Book Value ratio x1.73.9 44.4%  
Dividend payout %35.122.0 160.0%   
Avg Mkt Cap Rs m470,29232,272 1,457.3%   
No. of employees `0007.81.1 722.7%   
Total wages/salary Rs m22,504661 3,403.4%   
Avg. sales/employee Rs Th16,899.46,132.2 275.6%   
Avg. wages/employee Rs Th2,877.7611.1 470.9%   
Avg. net profit/employee Rs Th1,879.9803.5 234.0%   
INCOME DATA
Net Sales Rs m132,1536,635 1,991.8%  
Other income Rs m3,128242 1,291.0%   
Total revenues Rs m135,2816,877 1,967.1%   
Gross profit Rs m66,2901,604 4,132.2%  
Depreciation Rs m5,202221 2,349.4%   
Interest Rs m44,09738 116,969.2%   
Profit before tax Rs m20,1191,587 1,267.4%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,611718 1,199.4%   
Profit after tax Rs m14,701869 1,690.9%  
Gross profit margin %50.224.2 207.5%  
Effective tax rate %42.845.2 94.6%   
Net profit margin %11.113.1 84.9%  
BALANCE SHEET DATA
Current assets Rs m122,7426,232 1,969.5%   
Current liabilities Rs m310,8101,490 20,858.3%   
Net working cap to sales %-142.371.5 -199.1%  
Current ratio x0.44.2 9.4%  
Inventory Days Days2386 26.7%  
Debtors Days Days3983 47.0%  
Net fixed assets Rs m116,9044,043 2,891.3%   
Share capital Rs m369127 289.8%   
"Free" reserves Rs m272,1618,183 3,326.1%   
Net worth Rs m272,5308,310 3,279.6%   
Long term debt Rs m270,19618 1,517,956.2%   
Total assets Rs m856,26110,389 8,242.1%  
Interest coverage x1.543.1 3.4%   
Debt to equity ratio x1.00 46,285.0%  
Sales to assets ratio x0.20.6 24.2%   
Return on assets %6.98.7 78.6%  
Return on equity %5.410.5 51.6%  
Return on capital %12.419.5 63.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,2005,622 270.4%   
Fx outflow Rs m4,8891,799 271.7%   
Net fx Rs m10,3123,822 269.8%   
CASH FLOW
From Operations Rs m-115,975356 -32,623.0%  
From Investments Rs m-8,265-279 2,966.7%  
From Financial Activity Rs m107,525-225 -47,767.6%  
Net Cashflow Rs m-16,650-148 11,235.0%  

Share Holding

Indian Promoters % 52.9 63.4 83.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.0 -  
FIIs % 26.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 36.5 45.2%  
Shareholders   93,274 37,287 250.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  SUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 17, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS